Disclosure: No significant relationships.
Keywords: Psychoneuroimmunology; mindfulness; Selfmanagement; Autopoiesis

EPV0488

Efficacy of IV immunoglobulins on depressive symptoms and self-injury: A case report

A. Silva, P. Politi, N. Brondino and M. Olivola*

Department Of Brain And Behavioral Sciences, University of Pavia, Pavia, Italy

*Corresponding author.
doi: 10.1192/j.eurpsy.2021.2021

Introduction: Some studies in literature highlight the correlation between immune-mediated inflammatory processes and psychiatric pathologies. However, there are few studies about the efficacy of IV immunoglobulins in psychiatric features (1). (1) ZUNSZAIN, Patricia A.; HEPGUL, Nilay; PARIANTE, Carmine M. Inflammation and depression. In: Behavioral neurobiology of depression and its treatment. Springer, Berlin, Heidelberg, 2012. p. 135-151.
Objectives: Case report: a 39 year patient diagnosed with borderline personality disorder and myasthenia was hospitalized for self-injury ideation, acting out and depressive episode treated with acid valproic, aripiprazole, gabapentin; flare-up of myasthenia that needed treatment.
Methods: Clinical and test evaluation was performed in three stages: before (t0), immediately after (t1) and 3 weeks after (t2) the administration of the IgEV without other treatment modifications. We have used: - Inventory of Statements About Self-Injury (ISAS) - Barrat Impulsiveness Scale, Version 11 (BIS-11) - Hamilton Anxiety Rating Scale (HAM-A) - Montgomery-Asberg Depression Rating Scale (MADRS) - Alexian Brothers Urge to Selfe-Injure Scale (ABUSI)
Results: The patient has a score of 79 at BIS-11. She used to have a huge number of acting aout as we see on ISAS (Fig.1).
Figure 1

ISAS		
Self-Injury	Life time	t0-t2
Cutting	100	0
Biting	200	0
Carving	10	0
Pulling Hair	10	0
Severe Scratching	100	0
Banging or Hitting Self	250	0
Interfering/Would Healing	50	0
Rubbing Skin Againts Rough Surface	2	0
Sticking Self/Needles	5	0
Swallowing Dangerous Substance	300	0

Figure 2



Conclusions: We observed a reduction in non-suicidal self-injurious ideation, the suspension of acting-out, a complete remission of depressive symptoms with mild persistence of anxious symptoms immediately after the administration of immunoglobulins, and the remission continue until one month after the administration (Fig.2).

Disclosure: No significant relationships.
Keywords: acting-out; immunoglobulins; Borderline; Depression

EPV0489

Prospects for immunotherapy of depression based on cell technologies

E. Markova* and M. Knyazheva

Neuroimmunology Lab, State Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

*Corresponding author.
doi: 10.1192/j.eurpsy.2021.2022

Introduction: Cell technologies actively used in the treatment of many diseases. These technologies are based on manipulating the patient's cells outside the body, as a result of which cells acquire a higher therapeutic potential.
Objectives: No doubt the essential role of immune cells and their biologically active products in the pathogenesis of depression, which allows to view the modulated immune cells as model objects for developing new approaches to immunotherapy for depression.
Methods: (CBAxC57Bl/6) F1 depressive-like male mice, developed under the long-term social stress, were undergoing the transplantation of syngeneic immune cells with in vitro caffeine-modulated functional activity. Recipient's behavior, immune and nervous systems functional activity were studied.
Results: It was found that immune cells isolated from depressive-like mice and treated in vitro with caffeine change their properties and after intravenous administration to syngeneic depressive-like recipients have a significant positive psycho- and neuroimmunomodulatory effects, affecting the main depression pathogenetic mechanisms: behavioral editing (reduction of anhedonia, stimulation of exploratory behavior and activity in the forced swimming test); hippocampal neurogenesis stimulation against the background of increased BDNF; modulation of cytokine production by brain cells, indicating a decrease in neuroinflammation; modulation of the immune system functional activity (stimulation of the immune response, splenocytes proliferation, reducing systemic inflammation, decrease spleen tryptophan catabolism).
Conclusions: The results serve as an experimental substantiation of a fundamentally new approach to immunotherapy of depression based on the introduction of immune cells with functional activity modulated outside the body and open up the possibility of developing new methods of immunotherapy of depressive states in humans.

Disclosure: No significant relationships.
Keywords: modulated immune cells; Cell technologies; Depression; Immunotherapy

EPV0490

Human type 2 macrophages biologically active soluble products in the editing of stress-induced depressive-like behavior

E. Markova[1]*, E. Shevela[2], M. Knyazheva[1], I. Savkin[1], T. Amstislavskaya[3], A. Ostanin[2] and E. Chernykh[2]

[1]Neuroimmunology Lab, State Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation; [2]Cellular Immunotherapy Laboratory, State Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation and [3]Translational Biopsychiatry Lab, Research Institute of Neurosciences and Medicine, Novosibirsk, Russian Federation

*Corresponding author.
doi: 10.1192/j.eurpsy.2021.2023

Introduction: In the scientific world widely discussed phenomenon of "cytokine-induced depression". Macrophages have high plasticity and are able to control the inflammatory response; in particular, anti-inflammatory type-2 macrophages have a pronounced potential due to complex soluble factors production.
Objectives: We have developed an original method for the type-2 macrophages generation; the resulting macrophages are characterized by the high level of a whole range of neurotrophic, neuroprotective, proangiogenic and anti-inflammatory factors production. The aim of the study was to investigate effects of human type-2 macrophages soluble products on behavioral phenotype and brain cytokines synthesis in depressive-like animals.
Methods: Type-2 macrophages were generated by culturing an adherent fraction of mononuclear cells with 50 ng/ml recombinant human GM-CSF in serum deprivation conditions for 7 days. (CBA x C57Bl/6)F1 depressive-like male mice, developed under the long-term social stress, were undergoing the human type-2 macrophages conditioned medium intranasal administration (60 ml twice daily for one animal) for 6 days. Mice behavioral phenotyping was carried out using an automatic registration system (Noldus Information Technology). Cytokines were determined by ELISA.
Results: Depressive-like mice behavioral phenotyping after type-2 macrophages conditioned medium administration revealed anhedonia decrease, motor activity stimulation in the open field and forced swimming tests, anxiety reduction in elevated plus maze. Behavioral changes were recorded against the pro-inflammatory cytokines (TNF-α, IL-1β, IL- 6, INFγ) decrease in striatum and hippocampus, as well as anti-inflammatory IL- 10 increase in hippocampus and hypothalamus.
Conclusions: Results demonstrated the effectiveness of human type-2 macrophages biologically active soluble products in relation to the stress-induced depressive-like behavior editing

Disclosure: No significant relationships.
Keywords: anti-inflammatory macrophages; depressive-like behavior; cytokines

EPV0491

The role of inflammation in pathogenesis of juvenile schizophrenia

S. Zozulya[1]*, M. Omelchenko[2], I. Otman[1], A. Yakimets[2], Z. Sarmanova[1], V. Kaleda[2] and T. Klyushnik[1]

[1]Laboratory Of Neuroimmunology, Mental Health Research Centre, Moscow, Russian Federation and [2]Department Of Youth Psychiatry, Mental Health Research Centre, Moscow, Russian Federation

*Corresponding author.
doi: 10.1192/j.eurpsy.2021.2024

Introduction: Inflammation is now known to be a key factor in the development of schizophrenia. In this regard, the study of the pathogenic role of inflammation in the early stages of schizophrenic process is of particular importance, making it possible to assess its activity and to predict the development of the disease.
Objectives: To compare the dynamics of inflammatory markers in blood of first-episode psychosis (FEP) patients and people at risk signs for schizophrenia in the course of the treatment. Juvenile depression (JD) with attenuated symptoms of schizophrenic spectrum (ASSS) was investigated as a risk group.
Methods: The patients aged 17-25 years (20 people, of which 10 FEP patients (F20) and 10 JD with ASSS ones (F32.1-2, F32.38, F32.8)) were examined at admission to the hospital and at discharge. The controls consisted of 10 healthy volunteers. Symptom severity was collected using PANSS, SOPS, SANS, HDRS. The inflammation markers (TNF-α, IL-6, IL-10, leukocyte elastase (LE), CRP, α1-proteinase inhibitor (α1-PI), anti-S100-beta antibodies) were determined in blood.